pharmaphorum Daily newsletter - 12th Nov. 2024
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
Tuesday heralds news that AstraZeneca plans to invest a sizeable $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, its sights set on raising revenues to $80 billion by the end of the decade.
Elsewhere, NHS England has relaunched its anti-smoking pill programme, while the FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease who need dialysis.
Meanwhile, shares in AbbVie slumped following a pair of failed phase 2 trials for schizophrenia drug emraclidine, and 23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
In our longer reads today, we look at the ambitious targets and funding initiatives from the UN General Assembly on AMR, and today’s podcast looks at next generation wearables and how they’re transforming remote patient monitoring.
All this and more on pharmaphorum.com
News
AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end of the decade.
A daily pill that helps people stop smoking is to be offered by the NHS in England once again after it was withdrawn from sale in 2021 due to quality issues.
23andMe 's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
The FDA has started a review of Unicycive Therapeutics ' drug for hyperphosphataemia in patients with chronic kidney disease (CKD) who need dialysis, which hopes to improve on 'onerous' phosphate binder therapy.
Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.
Views & Analysis
In response to the rise of AMR, world leaders recently convened at the United Nations General Assembly to forge a landmark commitment, setting ambitious targets and funding initiatives to curb the spread of drug-resistant infection.
Artificial intelligence (AI) is transforming the pharmaceutical industry, revolutionising drug discovery and approval processes, and reshaping how researchers identify potential drug candidates, streamline clinical trials, and ensure regulatory compliance.
Drug manufacturers, wholesale distributors and pharmacies stepped up during the COVID-19 pandemic to preserve supply chain integrity. They were very particular about quality because the stakes were incredibly high.
Cloud-based labelling solutions provide secure access to approved suppliers and partners while offering numerous benefits to manufacturers.
Recommended by LinkedIn
For over 30 years, the US has clung to an outdated and misguided war on testosterone, lumping it in with the anabolic steroids that come under the 1990 Anabolic Steroid Control Act.
Podcasts & Videos
In today’s podcast, web editor Nicole Raleigh speaks with Dr Samuel Ewing, global head of pharma partnerships at Doccla , about the next generation of digital tools such as wearable medical devices, as well as remote patient monitoring and digital healthcare generally.
In another pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Neal Kassell, chair and founder of the Focused Ultrasound Foundation and previously a neurosurgeon, who created the Foundation in 2006 to improve the lives of millions of people with serious medical disorders by accelerating the development and adoption of focused ultrasound.
In this pharmaphorum podcast, web editor Nicole Raleigh speaks with Matt Hollingsworth, co-founder and CEO of Carta Healthcare, a company seeking to support the healthcare data registry market by transforming a previously manual clinical data abstraction process.
In a new podcast, web editor Nicole Raleigh speaks with Dr Evan Floden, CEO and co-founder of Seqera, a data orchestration and genomics analysis company, about barriers of entry to genomic surveillance in public health labs and how these can be lowered to support future bioinformaticians, aiding acceleration and quality and accuracy in R&D.
At LSX in Boston, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some recent news.
Webinars & White Papers
Join us NEXT WEEK, on Tuesday 19th November at 11am EST / 5pm CET / 4pm GMT, for a webinar sponsored by PurpleLab and learn how to gain a competitive edge by understanding physician prescribing behaviour in target markets.
In a webinar sponsored by Syneos Health - with Atlas Clinical Research’s Chief Executive Officer Mark Scullion, and Batisha Anson, Global Head of Patient Diversity and Health Equity at Syneos Health - learn more about the site experience for clinical research sites. Now available on demand.
Join us on Wednesday 4th December @ 2pm GMT - 3pm CET - 9am EST for an exclusive webinar, sponsored by Trueblue , to learn how life sciences organisations are leveraging the power of AI-driven strategic insights to revolutionise decision-making, enhance customer engagement, and gain a competitive edge.
Discover how to balance personalised engagement with regulatory compliance across global pharma markets in a webinar presented by EVERSANA INTOUCH . Available on demand now.
In a Socially Determined sponsored webinar, discover how industry leaders are harnessing non-clinical data to enhance recruitment, retention, and broader evidence generation. Now available on demand.